0001209191-19-054520.txt : 20191030 0001209191-19-054520.hdr.sgml : 20191030 20191030165148 ACCESSION NUMBER: 0001209191-19-054520 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191030 DATE AS OF CHANGE: 20191030 EFFECTIVENESS DATE: 20191030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trovagene, Inc. CENTRAL INDEX KEY: 0001213037 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 272004382 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-352221 FILM NUMBER: 191180862 BUSINESS ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-952-7570 MAIL ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TrovaGene Inc. DATE OF NAME CHANGE: 20110830 FORMER COMPANY: FORMER CONFORMED NAME: XENOMICS INC DATE OF NAME CHANGE: 20040719 FORMER COMPANY: FORMER CONFORMED NAME: USED KAR PARTS INC DATE OF NAME CHANGE: 20030106 D 1 primary_doc.xml X0708 D LIVE 0001213037 Trovagene, Inc. 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 (858) 952-7570 DELAWARE None TrovaGene Inc. XENOMICS INC USED KAR PARTS INC Corporation true Thomas H. Adams 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Executive Officer Director Brigitte Lindsay 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Executive Officer John P. Brancaccio 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Director Gary S. Jacob 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Director Rodney S. Markin 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Director Athena Countouriotis 11055 Flintkote Avenue San Diego CA CALIFORNIA 92121 Director Biotechnology Decline to Disclose 06b false 2019-10-30 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 420 Park Avenue New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK 5000000 5000000 0 false 2 1150000 true 0 Includes a cash fee of 7.5% of the aggregate gross proceeds raised in the offering including gross proceeds received from the cash exercise of warrants issued in the offering together with other expense reimbursement. 0 false Trovagene, Inc. /s/ Thomas H. Adams Thomas H. Adams Chief Executive Officer 2019-10-30